Advertisement

PharmacoEconomics & Outcomes News

, Volume 820, Issue 1, pp 19–19 | Cite as

Infliximab "most cost-effective option" in Crohn's disease

Clinical study
  • 4 Downloads

Reference

  1. Aliyev ER, et al. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naive Patients. Pharmacotherapy : 18 Dec 2018. Available from: URL: http://doi.org/10.1002/phar.2208

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations